SANTA CLARA, Calif. / Dec 10, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for... Read more
Analysis included 230 studies—a mix of randomized, prospective, and database research SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) --The peer-reviewed Annals of Surgery published a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures, comparing robotic, laparoscopic, and open surgical approaches. The study covered a 12-year timeframe and analyzed 230 studies from 22 countries: 34 randomized controlled trials, 74 prospective... Read more
A Total Knee Replacement Alternative for Patients with Metal and/or Bone Cement Sensitivities WARSAW, Ind., Dec. 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® SoluTion™ Porous Plasma Spray (PPS®) Femur, a total knee implant component offering an alternative for patients with sensitivities to bone cement... Read more
Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM, Dec. 4, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and beyond, today announced it has entered... Read more
WARSAW, Ind., Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for cementless partial knee replacement (PKR).1... Read more
Delivers solid results in Q4; initiates FY25 guidance Fourth-quarter fiscal year 2024 Revenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023. GAAP net income of $351 million; earnings per share (EPS) of $1.22, down 25% from the fourth quarter of 2023. Non-GAAP(2) net income of $418 million; EPS of $1.46, up 6% from the fourth quarter of 2023. Full fiscal year 2024 Revenue of $6.51 billion, down 4.7% on a reported basis... Read more
Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy drug – both of which are approved... Read more
The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve disease The investigational system is designed to offer best-in-class heart blood flow, ease of use and precision Approximately 9% of older Americans have aortic stenosis1 ABBOTT PARK, Ill., Nov. 25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the first patient procedures... Read more
LONDON / Nov 25, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. An analysis of data from more than 9,000 propensity-matched patients in the STS/ACC TVT Registry1 demonstrated that... Read more
New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system... Read more
Next generation of the Kendall™ SCD Series delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention DUBLIN, Ohio, Nov. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its Kendall SCD SmartFlow™ Compression System, the next generation of the Kendall™ Compression Series offering an enhanced clinician and patient experience. Featuring clinically proven technology that delivers customized,... Read more
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release T... Read more
FLOWER MOUND, Texas, USA, Nov. 19, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons to focus on delivering the highest standard of care. In today's operating rooms, where precision and accuracy are critical, even the smallest challenges may impact surgical outcomes – factors which may impede... Read more
Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, Nov. 19, 2024 /CNW/ -- Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024. Key Highlights Revenue of $8.4 billion increased 5.3% as... Read more
Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co-marketing efforts will help ŌURA and Dexcom reach millions of new users seeking better metabolic health Dexcom is investing $75 million in ŌURA Series D funding SAN DIEGO & SAN FRANCISCO / Nov 19, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose... Read more
WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. "After the successful introduction of Persona Revision Knee in the United States... Read more
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing... Read more
MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence,"... Read more
PORTAGE, Mich., USA, Nov. 14, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined... Read more
Streamlined solution for mitochondrial assessment democratizes cell analysis making it accessible to more researchers SANTA CLARA, Calif. / Nov 14, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all skill levels. With this cost-effective and versatile kit, researchers can easily incorporate... Read more
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA / Nov 12, 2024 / Business Wire / Alcon (SIX/NYSE:ALC), the global leader... Read more
Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategy Company announces plan to hold Investor Day in June 2025 DUBLIN, Ohio, Nov. 11, 2024... Read more
Baxter third-quarter 2024 sales totaled $3.85 billion1 Third-quarter total Baxter U.S. GAAP2 diluted earnings per share (EPS) were $0.271; adjusted total Baxter diluted EPS were $0.801, exceeding the company’s previously issued guidance Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis3, reflecting growth across all segments4 Third-quarter U.S. GAAP diluted EPS from continuing operations were... Read more
COLUMBUS, Ohio / Nov 07, 2024 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) today announced third quarter results for 2024. Provided below are the highlights: Reported and local currency sales increased 1% compared with the prior year. Net earnings per diluted share as reported (EPS) were $9.96, compared with $9.21 in the prior-year period. Adjusted EPS was $10.21, an increase of 4% over the prior-year amount of $9.80. Adjusted EPS is a non-GAAP measure,... Read more
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic Q4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectively FY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organic FY24 GAAP and adjusted diluted EPS from continuing operations of $5.93... Read more
PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision, even on day 71 Features world’s first ACTIV-FLO System specially designed for one-week optimal performance2 PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for comfort and affordability when a daily disposable lens is not an option1,3* GENEVA / Nov 07, 2024 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated... Read more
Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7% As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14 Fiscal 2025 outlook reiterated DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. Total revenue from continuing... Read more
Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024 Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billion Raised fiscal year... Read more
Collaboration to leverage Praia Health’s technology and Labcorp’s comprehensive testing capabilities to streamline and personalize patient experience CHICAGO & BURLINGTON, N.C. / Nov 04, 2024 / Business Wire / Praia Health, the consumer experience orchestration platform for health systems, is pleased to announce it has secured a strategic investment from the Labcorp Venture Fund and will collaborate with Labcorp, a global leader of innovative and comprehensive... Read more
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and... Read more
The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation (RDN) catheter, used in the Symplicity™ blood... Read more
Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expiration GAAP1 operating earnings were $568 million; GAAP diluted EPS was $1.70 Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profit Non-GAAP diluted EPS increased 9% to $1.88 Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90,... Read more
Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million,... Read more
WASHINGTON / Oct 30, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.... Read more
FRANKLIN LAKES, N.J., Oct. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched the new BD® Intraosseous Vascular Access System, enabling access for rapid delivery of fluids or medication in critical emergency situations. The procedure involves inserting a needle into the bone marrow cavity when intravenous (IV) access is challenging or delayed. The BD® IO System can quickly provide... Read more
Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency1 basis Third quarter diluted earnings per share were $1.23; adjusted1 diluted earnings per share were $1.74 Company updates 2024 financial guidance, reducing and narrowing range for full year outlook WARSAW, Ind., Oct. 30, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2024. ... Read more
Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Stryker reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billion Organic net sales increased 11.5% Reported operating income margin of 19.7% Adjusted operating income margin(1) increased 130 bps to 24.7% Reported EPS increased 20.0% to $2.16 Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overvi... Read more
New facility in Boylston increases U.S. warehouse capacity and expands specialized handling capabilities DUBLIN, Ohio, Oct. 29, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the grand opening of its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business. The facility provides healthcare customers in Massachusetts, New Hampshire, Rhode Island, Maine, Vermont and Eastern Connecticut with... Read more
MISSISSAUGA, ON, Oct. 29, 2024 /CNW/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today Health Canada approval of the BD Onclarity™ HPV Assay for human papillomavirus (HPV) testing for the use with self-collected vaginal specimens at home. Self-collected samples provide an alternative to the traditional Pap test performed by a clinician with a speculum, making cervical cancer screening more... Read more
Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial GALWAY, Ireland and WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity™ Spyral renal denervation... Read more
First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety and efficacy as well as improved workflow and short learning curve Now with two pulsed field ablation (PFA) offerings and a portfolio of electrophysiology solutions, Medtronic is shaping the future of arrythmia treatment today GALWAY, Ireland, Oct. 24, 2024 /PRNewswire/... Read more
IRVINE, Calif. / Oct 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in... Read more
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27% Operating cash flow of $326 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2024. First Quarter 2025 Highlights All comparisons are to the... Read more
SAN DIEGO / Oct 24, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic1 basis, all on a year-over-year basis. GAAP operating... Read more
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progression ABBOTT PARK, Ill., Oct. 24, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new, first-of-its-kind clinical trial designed to improve outcomes... Read more
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year: Revenue: $3.28 billion versus $3.06 billion Diluted EPS: $2.00 versus $2.11 Adjusted EPS: $3.50 versus $3.38 Free Cash Flow: $162 million versus $171 million Updated Full-Year 2024 Guidance: Revenue range of 6.6% to 7.3%; midpoint unchanged Adjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately... Read more
Conference Call Scheduled for 9 a.m. EDT Today EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%. Reported-diluted EPS of $1.85, compared to $2.14 in the same period last... Read more
Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted... Read more
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505... Read more
WALTHAM, Mass. / Oct 23, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Highlights Third quarter revenue was $10.60 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.25. Third quarter adjusted EPS was $5.28. Advanced our proven growth strategy, launching a range of high-impact, innovative... Read more
COPYRIGHT ©2023 HEALTH STOCKS HUB
